VHIO-BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI)

VHIO-led study unveils novel mechanism of resistance to T-cell bispecific antibodies and CAR-T targeting HER2 breast cancer

Redirection of lymphocytes, via T-cell bispecific antibodies (TCBs) and chimeric antigen receptors (CARs), is already approved to treat some hematologic…